Adenocarcinoma de pulmón pobremente indiferenciado. A propósito de un caso
Files
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
View full text
Date
Subject
tumor
malignant
adenocarcinoma
lung
undifferentiated
tumor
maligno
adenocarcinoma
pulmón
indiferenciado
malignant
adenocarcinoma
lung
undifferentiated
tumor
maligno
adenocarcinoma
pulmón
indiferenciado
Language:
Journal Title
Journal ISSN
Volume Title
Publisher
Intituto Tecnológico de Santo Domingo (INTEC)
El cáncer es una de las principales causas de muerte en el mundo. Es la neoplasia más frecuente y con mayor mortalidad en ambos sexos en los países desarrollados. Su pronóstico global es malo con una supervivencia total a los 5 años del 15%. Los factores de riesgo para el CP son diversos, pero destacan el tabaquismo, tanto activo como pasivo; exposición a radiación por gas radón; dieta; exposición a compuestos químicos como asbestos, arsénico, cloruro de vinilo, cromato de níquel, clorometilo de éter, entre muchas otras sustancias más. El CP se considera como enfermedad centinela del tabaquismo por las siguientes razones: 1. Fumar tabaco es el factor de riesgo presente en 90% de los pacientes con CP. 2. El riesgo de enfermar o morir por CP en fumadores aumenta drásticamente después de los 40 años de edad. 3. Las tasas de mortalidad por CP aumentan después de los 40 años de edad, en relación directa con el consumo de tabaco. 4. Después de 10 años de abstinencia, el riesgo relativo de desarrollar CP se reduce 50% en comparación con la persistencia en el hábito. El carcinoma no de células pequeñas de pulmón (CNCP) supone el 80-85% de los CP. Incluye fundamentalmente, los siguientes tipos histológicos: epidermoide, adenocarcinoma y de células grandes. A su presentación sólo el 25% son estadios localizados, y un 35% son estadios localmente avanzados (estadio III o IV). Aproximadamente el 80% de los pacientes con CNCP presentan enfermedad metastásica en alguna de sus fases evolutivas: 30-40% al diagnóstico, 50% por recidiva de los estadios I-II y 80% por progresión o recaída de los estadios III, y su supervivencia es muy pobre. El carcinoma de células pequeñas de pulmón (CCP) constituye aproximadamente el 15-20% de las neoplasias pulmonares. Aproximadamente el 60- 70% de los pacientes tienen enfermedad diseminada en el momento del diagnóstico.
Cancer is one of the leading causes of death in the world. It is the most frequent neoplasm and with the highest mortality in both sexes in developed countries. Its overall prognosis is poor with a 5-year total survival of 15%. The risk factors for PC are diverse, but they emphasize smoking, both active and passive; radiation exposure by radon gas; diet; exposure to chemical compounds such as asbestos, arsenic, vinyl chloride, nickel chromate, chloromethyl ether, among many other substances. CP is considered as a sentinel disease of smoking for the following reasons: 1. Tobacco smoking is the risk factor present in 90% of patients with PC. 2. The risk of getting sick or dying from PC in smokers increases dramatically after 40 years of age. 3. CP mortality rates increase after 40 years of age, directly related to tobacco use. 4. After 10 years of abstinence, the relative risk of developing CP is reduced by 50% compared to persistence in habit. Non-small cell lung carcinoma (CNCP) accounts for 80-85% of PC. It mainly includes the following histological types: epidermoid, adenocarcinoma and large cell types. At presentation only 25% are localized stages, and 35% are locally advanced stages (stage III or IV). Approximately 80% of patients with CNCP present metastatic disease in some of its evolutionary phases: 30-40% at diagnosis, 50% due to recurrence of stages I-II and 80% due to progression or relapse of stages III, and its Survival is very poor. Small cell lung carcinoma (PCC) constitutes approximately 15-20% of lung neoplasms. Approximately 60-70% of patients have disseminated disease at the time of diagnosis.
Cancer is one of the leading causes of death in the world. It is the most frequent neoplasm and with the highest mortality in both sexes in developed countries. Its overall prognosis is poor with a 5-year total survival of 15%. The risk factors for PC are diverse, but they emphasize smoking, both active and passive; radiation exposure by radon gas; diet; exposure to chemical compounds such as asbestos, arsenic, vinyl chloride, nickel chromate, chloromethyl ether, among many other substances. CP is considered as a sentinel disease of smoking for the following reasons: 1. Tobacco smoking is the risk factor present in 90% of patients with PC. 2. The risk of getting sick or dying from PC in smokers increases dramatically after 40 years of age. 3. CP mortality rates increase after 40 years of age, directly related to tobacco use. 4. After 10 years of abstinence, the relative risk of developing CP is reduced by 50% compared to persistence in habit. Non-small cell lung carcinoma (CNCP) accounts for 80-85% of PC. It mainly includes the following histological types: epidermoid, adenocarcinoma and large cell types. At presentation only 25% are localized stages, and 35% are locally advanced stages (stage III or IV). Approximately 80% of patients with CNCP present metastatic disease in some of its evolutionary phases: 30-40% at diagnosis, 50% due to recurrence of stages I-II and 80% due to progression or relapse of stages III, and its Survival is very poor. Small cell lung carcinoma (PCC) constitutes approximately 15-20% of lung neoplasms. Approximately 60-70% of patients have disseminated disease at the time of diagnosis.
Description
Type
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/publishedVersion
Source
Science and Health; Vol 3 No 1 (2019): Science and Health, january-april; 79-88
Ciencia y Salud; Vol. 3 Núm. 1 (2019): Ciencia y Salud, enero-abril; 79-88
2613-8824
2613-8816
10.22206/cysa.2019.v3i1
Ciencia y Salud; Vol. 3 Núm. 1 (2019): Ciencia y Salud, enero-abril; 79-88
2613-8824
2613-8816
10.22206/cysa.2019.v3i1